Pharma News | BioPharma Dive
3 days ago · GSK invests $800M in manufacturing; Amgen sets small discount for Eylea biosimilar. The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, Roche and Dyno expanded their alliance to create better viral vectors for use in gene therapy. By BioPharma Dive staff • Oct. 25, 2024.
BioMarin finally secures FDA approval of hemophilia gene therapy
Jun 29, 2023 · The Food and Drug Administration approved on Thursday the first gene therapy for the most common form of hemophilia, clearing the way for what patients, doctors and the medicine’s developer hope could be a one-time treatment for the rare bleeding disorder. BioMarin Pharmaceutical, the California-based company behind the therapy, plans to sell ...
Seagen’s cancer drug succeeds in ‘must-win’ trial
Sep 22, 2023 · Seagen’s cancer drug succeeds in ‘must-win’ trial. The study, which paired Merck’s Keytruda with Seagen’s Padcev in patients with previously untreated bladder cancer patients, is key to the latter drug’s commercial prospects, analysts say. A combination of cancer drugs from Seagen and Merck & Co. has shown early success in a large ...
Biotech and Pharma Industry News | BioPharma Dive
BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
The biopharma industry outlook on 2024: Guarded optimism for a …
Published Jan. 16, 2024. Ned Pagliarulo Lead Editor. Brian Tucker / BioPharma Dive. Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a ...
Novartis wins FDA approval for new heart drug, but faces uphill …
Dec 22, 2021 · Novartis priced Leqvio at $3,250 per dose for U.S. sale, meaning the first year of treatment will cost $9,750 and subsequent years $6,500. That’s slightly higher than the $5,400-per-year price that the Institute for Clinical and Economic Review, a watchdog group on drug costs, said would be cost effective for Leqvio when used broadly, but ...
With Aera, CRISPR pioneer Feng Zhang goes after gene therapy’s …
Feb 16, 2023 · The renowned MIT researcher’s latest startup has raised $193 million to develop a new way to shuttle gene-based medicines into the body. Aera Therapeutics emerged from the lab of Feng Zhang, a renowned CRISPR researcher at the Massachusetts Institute of Technology, and is headed by former Alnylam Pharmaceuticals executive Akin Akinc.
Lilly's closely watched diabetes drug scores in obesity trial
Apr 28, 2022 · Dive Brief: Eli Lilly’s experimental diabetes shot tirzepatide helped obese people who have an underlying medical condition lose more than 15% of their body weight in a late-stage clinical trial. At the highest dose tested, patients receiving the weekly injection lost, on average, 21% of their body weight, Lilly said in a press release Thursday.
Radiopharmaceuticals for cancer: Making radiation precise
Aug 15, 2023 · When the Food and Drug Administration approved a new prostate cancer drug last year, it validated a bet made by Novartis to acquire the drug’s maker, Endocyte. The decision was also another step forward for a long-studied research field that appears to finally be coming of age. The medicine, Pluvicto, is known as a “radiopharmaceutical.”.
8 key clinical trials to watch for the rest of 2021
Jun 21, 2021 · The first half of 2021 was historic for biotech. The Food and Drug Administration cleared the first new Alzheimer's drug in nearly two decades, a controversial decision with far-reaching consequences. Multiple effective coronavirus vaccines and antibody drugs helped bring the pandemic under control in the U.S., while the first-ever treatment for a common genetic driver of cancer won approval.